A study to find out whether treatment with finasteride can reduce blood loss in patients undergoing surgery for benign enlargement of prostate.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- All patients of benign prostatic hyperplasia recommended to undergo transurethral resection of prostate surgery will be included in study
- Registration Number
- CTRI/2016/06/006984
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 68
Inclusion Criteria
1. All consenting patients of BPH recommended in department of urology to undergo Transurethral resection of prostate with prostate size >30 gm as measured by transabdominal ultrasonography will be included in this study.
2.Drug (5 alpha reductase inhibitors) free period of 6 months
Exclusion Criteria
1. Patients with previous invasive procedures of the prostate.
2. Patients with known prostate cancer.
3. Patients who have received LHRH agonists, antiandrogens, estrogens, 5ARIs 4. Radiation therapy to pelvis
5. Patients allergic to finasteride
6.Patients on anticoagulant drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To measure the effect of finasteride on perioperative blood loss. <br/ ><br> <br/ ><br>2.To assess the effect on microvessel density on resected prostatic tissue in BPH patients by finasteride. <br/ ><br>Timepoint: N/A
- Secondary Outcome Measures
Name Time Method 1.To find out whether there is any correlation between blood loss and microvessel density in BPH patients who undergoes TURP. <br/ ><br>2.To find out any effect on perioperative serum sodium level. <br/ ><br>Timepoint: N/A